Patents Examined by Lianko Garyu
  • Patent number: 9896489
    Abstract: The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of and prevention of transmission of HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 20, 2018
    Assignee: Eastern Virginia Medical School
    Inventors: Edward M. Johnson, Dianne C. Daniel
  • Patent number: 9827286
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 28, 2017
    Assignees: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Patent number: 9815869
    Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 14, 2017
    Assignees: University of Rochester, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
  • Patent number: 9803193
    Abstract: The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: October 31, 2017
    Assignee: X-BODY, INC.
    Inventors: Richard W. Wagner, Alexander Litovchick, Yan Chen
  • Patent number: 9801949
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 31, 2017
    Assignee: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: Felix Kratz, Andre Warnecke
  • Patent number: 9796766
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 24, 2017
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
  • Patent number: 9782451
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: October 10, 2017
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Patent number: 9783578
    Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 10, 2017
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Suresh Kumar Vadlamani, Koteswara Rao Vemula, Leena Khare Satyam, Krishnaprasad Subbarao, K. Rajeev Shrimali, Sreenivas Kandepu
  • Patent number: 9765329
    Abstract: The present invention relates to a gene delivery system for targeting adipocytes and a treatment system for obesity and obesity-derived metabolic syndromes using the same and, more particularly, to a non-viral gene delivery system which directly targets a differentiated obesity (mature) adipocyte and contains an adipocyte targeting sequence (ATS)-arginine (R9) peptide.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: September 19, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Yong-Hee Kim, Kwang-Suk Lim, Young-Wook Won, Jang-Kyoung Kim
  • Patent number: 9757427
    Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: September 12, 2017
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony Coates
  • Patent number: 9746463
    Abstract: The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: August 29, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gerard Karsenty, Patricia F. Ducy
  • Patent number: 9724434
    Abstract: There is provided a lysine oligomer derivative, wherein an ?-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an ?-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 8, 2017
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Toshitaka Oohashi, Hiroki Kakuta
  • Patent number: 9713632
    Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 25, 2017
    Assignee: Hexima Limited
    Inventors: Nicole Louise Van Der Weerden, Marilyn Anne Anderson
  • Patent number: 9707269
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 18, 2017
    Assignee: CSL BEHRING GMBH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • Patent number: 9702883
    Abstract: The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: July 11, 2017
    Assignee: ABAXIS, INC.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Andrew P. Rogers, Timothy P. Forsyth, Jeremy D. Walker, Christina R. Cuesico
  • Patent number: 9688719
    Abstract: Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are substrate-competitive inhibitors and have an amino acid sequence designed so as to bind to a defined binding site subunit in GSK-3.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: June 27, 2017
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Hagit Eldar-Finkelman, Miriam Eisenstein
  • Patent number: 9683251
    Abstract: A method for the production of nucleic acid encoding a target protein. The method comprises (a) providing an array of RNA or DNA molecules including one or more encoding the target protein; (b) generating a target protein from the array to form RNA-protein or DNA-protein complexes in which the RNA or DNA molecule is non-covalently or covalently bound to the complex; (c) separating the complexes into compartments wherein most or all of the compartments contain no more than one complex; (d) subjecting the complexes to reaction conditions which allow target protein activity; and (e) selecting nucleic acid encoding the target protein on the basis of the activity associated therewith, wherein when the complex is a DNA-protein complex in which the DNA is non-covalently bound, step b) is performed in the absence of separate compartments for each complex.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 20, 2017
    Assignee: Thermo Fisher Scientific Baltics UAB
    Inventors: Arvydas Janulaitis, Remigijus Skirgaila, Dangira Siksniene
  • Patent number: 9682061
    Abstract: The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: June 20, 2017
    Assignee: THE MEDICINES COMPANY
    Inventors: Dario Lehoux, Thomas Parr, Jr., Gregory Moeck
  • Patent number: 9675960
    Abstract: The present invention refers to a method for binding a polycarboxylic acid to a solid phase. Further, the invention refers to a solid phase having a polycarboxylic acid immobilized thereto and methods of using the solid phase, e.g. for purifying His-tagged recombinant polypeptides.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: June 13, 2017
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Dirk Goerlich, Steffen Frey
  • Patent number: 9669074
    Abstract: The present invention provides a formulation comprising a corticosteroid and an insulin analog. Also provided is a formulation comprising a corticosteroid, an insulin analog and at least one organic acid. Further provided are pharmaceutical compositions of the formulations described herein. The present invention provides methods for stimulating bone and/or cartilage growth, for stimulating hair growth and/or reducing hair loss, for stimulating growth of a tooth and/or periodontium and for treating tumors and cysts of the jaw by administering the formulations described herein.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: June 6, 2017
    Inventors: Juan Paz Garcia, Brenda Astrid Paz Michel